Targeted therapy plus radiation for older adults with cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a targeted drug (nimotuzumab) combined with radiation therapy for older adults with cervical cancer. The goal is to improve treatment outcomes for those who cannot tolerate chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years of age or older.
- You have cervical squamous cell carcinoma that has not spread to distant organs.
- You are unable to receive or choose not to receive chemotherapy.
- You have not had any previous treatment for cervical cancer.
- You are able to undergo an MRI of the pelvis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called nimotuzumab combined with radiation therapy for older adults (65+) with advanced head and neck cancer. It aims to help control the cancer when chemotherapy is not an option.
This trial tests adding the targeted drug nimotuzumab to standard chemotherapy and radiation for people with esophageal cancer that cannot be removed by surgery. It may help shrink the tumor or stop it from growing further.
This trial tests a drug called nimotuzumab combined with standard chemotherapy and radiation for patients with esophageal cancer. It may help improve treatment effectiveness for those whose cancer has not spread to other parts of the body.
This trial is testing a combination of standard chemotherapy and radiation delivered to the pelvis, followed by an internal radiation treatment guided by CT scans. The goal is to improve treatment for locally advanced cervical cancer while potentially reducing side effects.
This trial tests adding a targeted drug called nimotuzumab to the standard chemoradiotherapy for cervical cancer, followed by ongoing maintenance treatment. It aims to see if this combination helps control the cancer better than chemoradiotherapy alone.
This trial tests adding nimotuzumab, a targeted therapy, to standard chemoradiation for elderly patients with esophageal squamous cell cancer. It aims to see if the combination improves outcomes.
Hear when a new Cervical Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.